Current position

The Vanguard Group, Inc.’s Eli Lilly (LLY) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

The Vanguard Group, Inc.Verified through Q4 2025
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2014Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares81.97MHighest verified quarter-end share count
Quarters reported46Verified quarters with shares above zero
What happened?

The Vanguard Group, Inc. first reported Eli Lilly in Q3 2014. The reported position was increased and reduced across later filings. The Vanguard Group, Inc. currently reports 81.97M shares. The latest verified filing showed: Bought 1.2% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q4 2025
Bought 1.2% more+1.01M shares · 81.97M shares reported after the change
Filing context

Quarter-end price $1,074.68

Q3 2025
Bought 0.7% more+551.66K shares · 80.96M shares reported after the change
Filing context

Quarter-end price $763.00

Q2 2025
Bought 1.5% more+1.18M shares · 80.41M shares reported after the change
Filing context

Quarter-end price $779.53

Q1 2025
Bought 6.7% more+4.98M shares · 79.22M shares reported after the change
Filing context

Quarter-end price $825.91

Q4 2024
Bought 0.6% more+475.53K shares · 74.25M shares reported after the change
Filing context

Quarter-end price $772.00

Q3 2024
Sold 0.1% of the position−85.54K shares · 73.77M shares remained
Filing context

Quarter-end price $885.94

Portfolio importance

How important is Eli Lilly in The Vanguard Group, Inc.’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight1.3%Q4 2025
Current rank#10of 4329 reported positions
Peak portfolio weight1.3%Q2 2024
Best historical rank#9Q2 2024
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$1,164.892026-09-21

Market context only; not an investor transaction price.

Latest filing quarter-end price$1,074.68Q4 2025

Derived from validated reported value and shares where supported.

Latest verified investor filingQ4 2025 · filed 2026-01-29
Open SEC filing ↗

View Eli Lilly stock page →

Coverage is bounded to Vanguard’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Vanguard’s complete global assets, fund-by-fund ownership, exact trade dates or execution prices.